首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared WithBasal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type2 Diabetes in the DUAL VII Randomized Trial

【2h】

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared WithBasal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type2 Diabetes in the DUAL VII Randomized Trial

机译：胰岛素Degledec / Liraglutide（Ideglira）的益处与基础推子胰岛素治疗伴随着类型的参与者子组一致两种糖尿病在双重VII随机试验中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin(HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessedthe effect of once-daily IDegLira compared with BB (once-daily insulinglargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups withvarying characteristics.

机译：胰岛素Degludec / Liraglutide（Ideglira）导致糖化血红蛋白（HBA1C）水平与基底推注（BB）疗法相当。在这里，我们评估了与BB相比，曾经每日IDEglira的效果（曾经 - 每日胰岛素在亚组中，狼氨酸100 u / ml和胰岛素Aspart≤4次/天）不同的特点。

著录项

期刊名称 Journal of Diabetes Science and Technology
作者
Liana K. Billings; Bue F. Ross Agner; Yuksel Altuntas; Randi Grøn; Natalie Halladin; David C. Klonoff; Nikolaos Tentolouris; Esteban Jódar;
展开▼
作者单位

展开▼
年(卷),期 2021(15),3
年度 2021
页码 636–645
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词

机译：GLP-1模拟;胰岛素治疗;Liraglutide;随机试验;2型糖尿病;

相似文献

外文文献

1. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial [J] . Liana K. Billings, Bue F. Ross Agner, Yuksel Altuntas, Journal of Diabetes Science and Technology . 2021,第3期

机译：胰岛素Degludec / Liraglutide（IDEGLIRA）与基础推子胰岛素治疗相比的益处是在与双七型随机试验中的2型糖尿病的参与者亚组中一致
2. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐na?ve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [J] . Kaku Kohei, Araki Eiichi, Tanizawa Yukio, Diabetes, obesity & metabolism . 2019,第12期

机译：与胰岛素Degludec和Liragludec和Liraglutide在胰岛素-Na've的胰岛素Degludec和Liraglutide中的胰岛素-Na've日本患者的胰岛素Degludec和Liraglutide的卓越疗效卓越的疗效与第3型糖尿病患者，开放标签，随机试验
3. Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50?units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial [J] . Watada Hirotaka, Kaneko Shizuka, Komatsu Mitsuhisa, Diabetes, obesity & metabolism . 2019,第12期

机译：优质的HBA1C控制与胰岛素Degludec和Liraglutide（IDEGLIRA）的固定比例组合，与最大剂量为50岁？在第3期患有2型糖尿病的日本人中胰岛素Degludec的单位，双盲，随机试验
4. Comparing artificial pancreas controlled by hybrid "closed-loop" machine learning (ML) trained algorithm to multi-daily injection (MDI), insulin pump without CGM and "sensor assisted" insulin pump therapies for Diabetes Type 1 (DT1) treatment [C] . Joan Carles Peiró International Conference on Data Analytics for Business and Industry: Way Towards a Sustainable Economy . 2020

机译：将通过混合“闭环”机器学习（ML）控制的人工胰腺培训算法对多日注于多日注射（MDI），胰岛素泵而没有CGM和“传感器辅助”胰岛素泵疗法1型（DT1）处理
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial [O] . Sultan Linjawi, Bruce W. Bode, Louis B. Chaykin, 2017

机译：IDegLira（胰岛素Degludec / Liraglutide联合用药）对GLP-1受体激动剂和口服疗法控制不佳的2型糖尿病成人的疗效：DUAL III随机临床试验
7. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [O] . Kohei Kaku, Eiichi Araki, Yukio Tanizawa, 2019

机译：与胰岛素Degludec和Liraglutide（IDEGLIRA）的胰岛素Degludec和Liraglutide在胰岛素-Naïve日本患者中的胰岛素Degludec和Liraglutide中的胰岛素-Naïve，在第3型糖尿病中，开放标签，随机试验

The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared WithBasal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type2 Diabetes in the DUAL VII Randomized Trial

摘要

著录项

相似文献

相关主题

期刊订阅